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ABSTRACT 
Severe PPHTN is a contraindication to liver transplantation and predicts an abysmal 5‐year 
outcome. It is defined as a resting mPAP >45 mm Hg with a mean pulmonary artery wedge 
pressure of <15 mm Hg and pulmonary vascular resistance of >3 wood units in the setting of 
portal hypertension. There have been limited reports of successful treatment of PPHTN leading 
to successful liver transplantation in adults, and one reported use of monotherapy as a bridge to 
successful liver transplant in pediatrics. To our knowledge, we describe the first use of 
combination therapy as a successful bridge to liver transplantation in a pediatric patient with 
severe PPHTN. This report adds to the paucity of data in pediatrics on the use of pulmonary 
vasodilator therapy in patients with severe PPHTN as a bridge to successful liver transplantation. 
Early diagnosis in order to mitigate or avoid the development of irreversible pulmonary 
vasculopathy that would preclude candidacy for liver transplantation is crucial, but our report 
demonstrates that combination therapy can be administered safely, quickly, and may allow for 
successful liver transplantation in patients with severe PPHTN. 
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1. INTRODUCTION 
PPHTN is a potentially fatal complication in patients with chronic liver disease,1 defined 
as a resting mPAP ≥25 mm Hg, a mean pulmonary artery wedge pressure of ≤15 mm Hg, 
and pulmonary vascular resistance >3 wood units in the setting of portal hypertension. 
The clinical symptoms are often insidious, making the initial diagnosis elusive. Prognosis 
varies depending on the severity of liver disease and response to pulmonary hypertension 
therapy and/or liver transplantation, and 5‐year survival is reported between 14% and 
40%.2-5 Liver transplantation with reversal of portal hypertension offers the highest 
likelihood of survival. Unfortunately, those who develop severe PPHTN are often 
prospectively excluded from transplantation secondary to unacceptably high mortality 
rates.1 
There have been successful reports of intravenous epoprostenol, sildenafil, or treprostinil 
allowing successful liver transplantation in adult patients with varying degrees of 
portopulmonary hypertension.6-10 A single case report of successful use of epoprostenol 
in a pediatric patient exists,11 and there are no reports of pediatric patients treated with 
early combination therapy for severe portopulmonary hypertension surviving to 
transplant. We report a 15‐year‐old female with idiopathic cirrhosis and severe PPHTN 
treated with treprostinil, tadalafil, and macitentan prior to successful orthotopic liver 
transplant and hospital discharge and whose medications were weaned and discontinued 
several months after transplant. 
2 CASE REPORT 
Our patient is a 15‐year‐old female with idiopathic cirrhosis diagnosed at 8 months of age. 
An echocardiogram performed at the time of diagnosis showed normal cardiac anatomy 
and function. Her course was complicated by portal hypertension as evidenced by 
multiple episodes of variceal rupture and need for variceal banding at the age of 5 years. 
She had spontaneous formation of a portal vein to IVC shunt noted in 2009. 
Her medications included phytonadione 5 mg twice daily, propranolol 30 mg twice daily, 
coenzyme Q10 200 mg daily, zinc sulfate 110 mg daily, and vitamin A, D, and E 
supplementation. She was doing well until she developed a persistent cough, which did 
 
 
not improve with a course of azithromycin. A chest X‐ray showed a nodular mass‐like 
appearance in the left hilum thought to be reflective of enlargement of the pulmonary 
artery (Figure 1). A CT of the chest showed markedly dilated central pulmonary 
vasculature consistent with pulmonary hypertension (Figure 2) and no evidence of filling 
defects. An echocardiogram showed normal left ventricular function, RV/PA systolic 
pressures of 75‐85 mm Hg based on TR, pulmonary artery diastolic pressures between 
30‐40 mm Hg based on pulmonary regurgitation, and a moderately hypertrophied right 
ventricle with mildly diminished systolic function. Right‐sided hemodynamics were 
assessed by cardiac catheterization and confirmed severe pulmonary hypertension and 
increased pulmonary vascular resistance with mild response to iNO and oxygen 
(Table 1). She was admitted for initiation of pulmonary vasodilator therapy. Previous 
workup for her cirrhosis found no evidence of infectious hepatitis nor autoimmune 
hepatitis, making an autoimmune etiology for her pulmonary hypertension unlikely. 
Spirometry was suggestive of mild restrictive physiology with FVC of 60% predicted, 
FEV1 of 59% predicted, and an FEV1/FVC ratio of 88%. A polysomnogram showed mild 
obstructive sleep apnea with an apnea hypopnea index of 3.9 per hour on room air and 
low mean oxygen saturations consistent with pulmonary vascular disease. Additional 
workup excluded infectious etiologies such as HIV, a hypercoagulable state or 
thromboembolic phenomena, pregnancy, and thyroid disease. A BNP on admission was 
1977 pg/mL, and 6MW distance was significantly diminished at 299 m while receiving 2 L 
oxygen by nasal cannula. 
 
 
 
Figure 1 
Chest X‐ray showing mass‐like area in the left hilar region representing aneurysmal 
change in the pulmonary artery secondary to pulmonary hypertension 
 
Figure 2. 
CT scan showing a markedly dilated pulmonary artery measuring 4.2 cm in diameter. The 
left and right pulmonary arteries are also markedly dilated 
Table 1. Right and left heart hemodynamics before and after pulmonary vasodilator 
therapy 
Measurements Initial 
diagnosis 
Initial diagnosis—40 ppm NO, 
100% FiO2 
Two months post‐
treatment 
Pulmonary vascular 
resistance 
16.75 13.78 2.38 
PVR/SVR ratio 0.92 0.83   
Mean pulmonary artery 
pressure 
72 62 27 
 
 
Measurements Initial 
diagnosis 
Initial diagnosis—40 ppm NO, 
100% FiO2 
Two months post‐
treatment 
Capillary wedge pressure 11 10 14 
Transpulmonary gradient 61 51 13 
Cardiac Index 3.64 3.77 5.89 
Right ventricular pressure 91/68 79/11 35/13 
Aorta blood pressure 97/60 84/60 95/40a 
 
• Units: pulmonary vascular resistance—woods units × m2; all intracardiac pressures are 
expressed in mm Hg; cardiac index—L/min/m2. 
• Abbreviations: FiO2, fraction of inspired oxygen; NO, nitric oxide; ppm, parts per million; 
PVR, pulmonary vascular resistance; SVR, systemic vascular resistance. 
• a The aorta blood pressure done at 2 mo post‐treatment is a non‐invasive measurement. 
She was initiated on milrinone at 0.3 mcg/kg/min, subcutaneous treprostinil at an infusion 
rate of 2.1 ng/kg/min, and tadalafil 40 mg daily. Her treprostinil dose was initially quickly 
increased but had to be slowed secondary to side effects including headache, nausea, 
diarrhea, tachycardia, and systemic hypotension. The milrinone infusion was stopped, 
and she was started on low dose dopamine at 3 mcg/kg/min as her treprostinil was 
increased. She was also started on furosemide and spironolactone, though furosemide 
was discontinued. She was discharged on treprostinil at 23.5 ng/kg/min and tadalafil 
40 mg daily. ERA therapy was not started due to elevated serum alanine and aspartate 
aminotransferase levels of 82 and 108 mg/dL, respectively, and a bilirubin level of 
8.7 mg/dL. Nocturnal CPAP at 6 cm H2O with 2‐3 L of oxygen was initiated, which 
markedly improved her cough. 
 
 
At follow‐up 12 days after discharge, an echocardiogram showed significant improvement 
in right ventricular pressure (Figure 3). Due to continued gastrointestinal side effects, 
treprostinil was decreased to 21.4 ng/kg/min. She had significant improvement in serum 
ALT and AST (31 and 41 mg/dL, respectively) and a bilirubin level of 2.4 mg/dL, so she 
was started on macitentan 5 mg daily and increased to 10 mg daily after two weeks. She 
underwent repeat cardiac catheterization approximately 2 months after starting 
pulmonary vasodilator therapy, which showed marked improvement in her 
hemodynamics (Table 1). 
 
Figure 3. 
Parasternal short‐axis view (A) with flattening of the interventricular septum and a dilated, 
hypertrophied right ventricle. After initiation of pulmonary vasodilator therapy, there is 
significant improvement in the septal position and right ventricular size (B) 
One month after cardiac catheterization, she was admitted to the hospital for acute 
cholecystitis. She was managed medically until a liver donor offer became available 
7 days later. One day prior to liver transplantation, she was transitioned from 
subcutaneous to intravenous treprostinil therapy without incident. A Swan‐Ganz catheter 
was placed in the operating room via the right internal jugular vein approach prior to 
initiation of the transplant surgery, demonstrating a mPAP of 32 mm Hg, right atrial 
pressure of 10 mm Hg, and pulmonary artery wedge pressure of 8 mm Hg. During the 
surgery, mean pressure rose to 15 mm Hg in the right atrium and 37 in the pulmonary 
artery. Inhaled nitric oxide was initiated with no immediate effect. Thirty minutes later, the 
hemodynamics returned to baseline. In the immediate post‐operative period, she spent 
 
 
6 days in the intensive care unit followed by 6 days on the cardiac step‐down unit. Enteral 
phosphodiesterase inhibitor and ERA therapies were continued on post‐operative day 2 
as iNO was weaned off. Intravenous treprostinil was transitioned back to subcutaneous 
treprostinil on post‐operative day 3, and she was discharged on post‐operative day 13. 
She was followed closely in our multidisciplinary pulmonary hypertension outpatient clinic 
and is now 18 months post‐transplant. Management of her pulmonary hypertension 
therapy was based on clinical symptoms and objective measurements such as 
echocardiography, 6MW, and spirometry. At her first outpatient visit 3 weeks post‐
transplant, she had no significant clinical symptoms and a predicted right ventricular 
pressure that was 1/3 her systemic pressure based on TR jet velocity, so a 5‐week wean 
of her treprostinil was initiated and completed without worsening clinical symptoms or 
pulmonary hypertension as assessed by echocardiogram. 6MW test remained improved 
from baseline at the first clinic visit off of treprostinil, with a distance of 487 m. Over the 
next several months, she showed a steady improvement in right ventricular size, function, 
and pressure along with a sustained improvement in clinical symptoms and improvement 
in spirometry with an FEV1 ~85%. By 6 months post‐transplant, she had returned to half 
days at school and successfully weaned off her Macitentan. At 16 months post‐transplant, 
her echocardiogram showed normal right ventricular size, function, and pressure and she 
tolerated discontinuation of her tadalafil. 
3 DISCUSSION 
Portopulmonary hypertension occurs independent of the cause of portal hypertension and 
does not seem to correlate with the severity of liver disease. It is categorized as mild, 
moderate, or severe based on the pulmonary artery pressure measurements.11, 12 The 
mechanism of PPHTN development is multifactorial and likely related to endotoxins and 
cytokines released secondary to overload of the splanchnic vasculature. These mediators 
bypass the liver and have direct effects on the pulmonary vasculature, including 
pulmonary vasoconstriction. It is also theorized that endotoxins lead to pulmonary 
vasodilation, which when coupled with the sheer stress associated with the high cardiac 
output state of liver failure, causes endothelial damage and pulmonary vascular 
remodeling. 
 
 
Due to the subtle clinical presentation of PPHTN, patients often have moderate‐to‐severe 
disease at the time of diagnosis, precluding them from liver transplant. Current guidelines 
recommend liver transplantation in patients with a mean pulmonary artery pressure 
<35 mm Hg or in patients with a mean PAP between 35 and 50 mm Hg with a PVR of <3 
wood units.13 
While PPHTN is not a sole indication for liver transplantation in adults,1 the 2014 Practice 
Guidelines for pediatric liver transplantation recommend that children with the evidence 
of PPTHN be promptly referred for liver transplant evaluation and that listed patients with 
severe PPHTN who are responsive to medical therapy qualify for a model for end‐stage 
liver disease score exception to receive a liver transplant.14 Our hepatology service felt 
that the severity of her PPHTN and degree of liver failure warranted proceeding with listing 
for liver transplantation. 
Reports of PPHTN and treatment in the pediatric population are limited. The multi‐center 
PPHTN database published in 2004 did not include any children. Losay et al15 published 
their experience with liver transplant in three children who did not receive pre‐operative 
pulmonary hypertension therapy. Condino et al16 described the clinical course, 
evaluation, and management of seven pediatric patients with severe PPHTN, four of 
whom died and none of whom were eligible for liver transplant despite medical therapy. 
To date, the only successful liver transplant reported in a pediatric patient with severe 
PPHTN was accomplished after four months of intravenous epoprostenol.11 
Our patient had severe PPHTN with mild reduction in mPAP and PVR with the 
administration of 100% oxygen and iNO. Although our patient's chest X‐ray was grossly 
abnormal, echocardiography remains the best screening tool for PPHTN.17 This report 
underscores the importance of periodic screening in this patient population. By using a 
combination of enteral and parenteral therapies, each targeting different pathways that 
lead to pulmonary vasodilation, we were able to successfully lower our patient's 
pulmonary artery pressure from severe to a level acceptable for liver transplantation after 
2 months of treatment. Further, we were able to interchange subcutaneous therapy with 
intravenous therapy to avoid problems with subcutaneous absorption that may have been 
associated with significant fluid shifts in the post‐operative state. Significant side effects 
 
 
associated with treprostinil initiation necessitated slow titration. In the face of her 
underlying liver disease and the fact that treprostinil is largely metabolized by the liver, a 
slower increase in this medicine may have minimized the amount of side effects that she 
experienced. Eventually, her aminotransferase and total and direct bilirubin levels 
improved with treatment, and she tolerated initiation of an endothelin receptor antagonist 
without detrimental hepatotoxicity. Although some have proposed that a mutation in the 
bone morphogenetic protein receptor type 2 may be a key factor in idiopathic pulmonary 
hypertension,18 our patient was negative for mutations in this gene and it has never been 
implicated in PPHTN. 
Lastly, while our patient demonstrated sustained improvement in her PPHTN and proved 
able to come off all of her therapy, we heed caution when considering aggressively 
weaning therapy in the first several months post‐transplant. While liver transplantation 
can reverse portal hypertension, the remodeling of the vasculature that results in 
pulmonary hypertension can sometimes prove to be irreversible.19 Clinicians should 
base their weaning schedule on patient symptoms and objective data such as 
echocardiogram, 6MW, PFTs, and catheterization‐based hemodynamics, when needed. 
This report adds to the sparse data on successful use of pulmonary vasodilator therapy 
as a means to improve right‐sided hemodynamics prior to liver transplant in pediatric 
patients with severe PPHTN. It is the first report that describes the successful use of early 
combination therapy to treat severe PPHTN as a bridge to successful liver 
transplantation. The optimum strategy appears to be early identification and aggressive 
monitoring with therapies as indicated in order to avoid the development of irreversible 
pulmonary vasculopathy. Our report demonstrates that, even if PPHTN is severe, 
aggressive triple therapy can be administered safely, quickly, and may allow for 
successful liver transplantation. 
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